Affinage

POLA1

DNA polymerase alpha catalytic subunit · UniProt P09884

Length
1462 aa
Mass
165.9 kDa
Annotated
2026-06-10
100 papers in source corpus 5 papers cited in narrative 5 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

POLA1 encodes the catalytic subunit of DNA polymerase alpha, which together with the primase complex initiates DNA replication, and which possesses intrinsic primer extension (DNA polymerase) activity demonstrable in vitro (PMID:33392852, PMID:34772529). Partial loss-of-function caused by a recurrent intronic mutation that misspices POLA1 underlies X-linked reticulate pigmentary disorder (XLPDR), an interferonopathy marked by profound type I interferon activation and Natural Killer cell dysfunction (PMID:33392852); consistent with this, pharmacologic inhibition of POLA1 upregulates interferon-alpha in immunocompetent mice, linking reduced POLA1 activity to type I interferon induction (PMID:34772529). POLA1 abundance is set post-transcriptionally: SNRPB promotes inclusion of POLA1 exon 3, and SNRPB silencing drives exon skipping that introduces a premature termination codon, triggering nonsense-mediated decay and lowering POLA1 protein, an axis that contributes to SNRPB-driven malignancy in ovarian cancer cells (PMID:37391593). Functionally, POLA1 operates alongside the ATR-CHK1 DNA damage response: it is synthetically lethal with ATR loss, and its depletion sensitizes cells to ATR and CHK1 inhibition through S-phase arrest and apoptosis (PMID:39128273). Complete absence of POLA1 is incompatible with viability, with heterozygous deletion in females producing subfertility and hemizygous nullisomy inferred to be embryonic lethal in males (PMID:36182037).

Mechanistic history

Synthesis pass · year-by-year structured walk · 5 steps
  1. 2021 Medium

    Established that partial POLA1 deficiency is not merely a replication defect but drives a defined human interferonopathy, connecting a core replication enzyme to innate immune dysregulation.

    Evidence Human genetic analysis of XLPDR patients with NK cell functional assays and interferon pathway measurements

    PMID:33392852

    Open questions at the time
    • Molecular trigger linking reduced POLA1 to type I interferon induction not defined
    • Why NK cells are selectively impaired not established
    • Reviewed synthesis rather than single primary dataset
  2. 2021 Medium

    Confirmed POLA1 intrinsic primer extension catalytic activity in vitro and showed that inhibiting this activity induces interferon-alpha in vivo, providing a causal link between POLA1 enzymatic output and interferon induction.

    Evidence In vitro POLA1 primer extension assay, molecular docking, and IFN-alpha ELISA in immunocompetent mice treated with dual POLA1-HDAC11 inhibitors

    PMID:34772529

    Open questions at the time
    • Dual POLA1-HDAC11 inhibitors confound attribution of IFN effect to POLA1 alone
    • Downstream sensor coupling reduced polymerase activity to IFN not identified
  3. 2022 Low

    Defined the viability requirement for POLA1, distinguishing tolerated partial loss from lethal complete loss and explaining the X-linked inheritance pattern.

    Evidence Clinical and genomic characterization of a three-generation family with Xp22.11-p21.3 microdeletion plus X-inactivation skewing analysis

    PMID:36182037

    Open questions at the time
    • Single family report with male lethality inferred from absence of affected males, not directly demonstrated
    • Deletion spans additional genes beyond POLA1
    • No cellular or biochemical mechanism for the subfertility phenotype
  4. 2023 Medium

    Revealed that POLA1 protein level is controlled post-transcriptionally by splicing, placing it downstream of an SNRPB-regulated exon-inclusion/NMD axis relevant to cancer malignancy.

    Evidence RNA-seq, RT-PCR, siRNA knockdown with rescue, cycloheximide NMD assay, and POLA1 knockdown epistasis in SNRPB-overexpressing ovarian cancer cells

    PMID:37391593

    Open questions at the time
    • Single lab and single cancer context
    • Whether this splicing axis operates in normal tissues not addressed
  5. 2024 Medium

    Positioned POLA1 as a functional partner of the ATR-CHK1 replication stress response, identifying a synthetic-lethal vulnerability with therapeutic potential.

    Evidence ATR-deficient DLD-1 model with chemical and siRNA POLA1 depletion, reciprocal sensitization to ATR/CHK1 inhibitors, and FACS cell-cycle/apoptosis analysis

    PMID:39128273

    Open questions at the time
    • Single cell-line context
    • Mechanistic basis of the synthetic lethality (replication catastrophe vs checkpoint loss) not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular mechanism coupling reduced POLA1 polymerase activity to type I interferon sensing and to selective NK cell impairment remains unresolved.
  • No identified nucleic acid sensor linking POLA1 deficiency to IFN
  • No structural model of POLA1 in the primase-polymerase initiation complex in this corpus
  • Cell-type basis of immune phenotypes uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140097 catalytic activity, acting on DNA 2
Pathway
R-HSA-69306 DNA Replication 2
Partners
ATRCHK1SNRPB
Complex memberships
DNA polymerase alpha-primase

Evidence

Reading pass · 5 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2021 POLA1 encodes the catalytic subunit of DNA polymerase alpha, which together with the Primase complex initiates DNA replication. A recurrent intronic mutation causing missplicing of POLA1 underlies X-linked reticulate pigmentary disorder (XLPDR), which is accompanied by profound activation of type I interferon signaling and marked Natural Killer (NK) cell dysfunction, establishing that partial POLA1 deficiency drives an interferonopathy with specific immune cell impairment. Human genetic analysis of XLPDR patients combined with functional immunological characterization (NK cell functional assays, interferon pathway activation measurements) Journal of clinical immunology Medium 33392852
2023 SNRPB silencing induces skipping of exon 3 of POLA1, which generates a premature termination codon and triggers nonsense-mediated RNA decay (NMD) of POLA1 mRNA, thereby reducing POLA1 protein levels and impairing DNA replication. POLA1 knockdown partially reversed the increased malignancy conferred by SNRPB overexpression in ovarian cancer cells, placing POLA1 downstream of SNRPB in this splicing-regulated pathway. RNA-seq and RT-PCR to detect exon skipping; siRNA knockdown of SNRPB with rescue experiments; NMD demonstrated by cycloheximide treatment; POLA1 knockdown epistasis in SNRPB-overexpressing cells Oncogene Medium 37391593
2024 POLA1 and ATR exhibit synthetic lethality: ATR-deficient cancer cells show markedly increased sensitivity to chemical POLA1 inhibition or siRNA-mediated POLA1 depletion, with cell death involving S-phase arrest and apoptosis. Conversely, siRNA-mediated POLA1 depletion sensitizes cancer cells to ATR and CHK1 inhibitors, establishing POLA1 as a functional partner of the ATR-CHK1 DNA damage response pathway. ATR-deficient DLD-1 cell model; chemical POLA1 inhibition; siRNA-mediated POLA1 knockdown; FACS-based cell cycle and apoptosis analysis; Western blotting for apoptotic markers Neoplasia Medium 39128273
2021 POLA1 has primer extension (DNA polymerase) activity that can be inhibited by small-molecule dual POLA1-HDAC11 inhibitors (MIR002, GEM144). Inhibition of POLA1 in immunocompetent mice significantly upregulated interferon-alpha, consistent with the model that reduced POLA1 activity promotes type I interferon induction. In vitro POLA1 primer extension functional assay; molecular docking; in vivo xenograft models; IFN-alpha ELISA in immunocompetent mice after POLA1 inhibitor treatment European journal of medicinal chemistry Medium 34772529
2022 Heterozygous deletion of POLA1 in females with skewed X-inactivation results in subfertility as the only phenotype, while hemizygous POLA1 nullisomy in males is inferred to cause very early embryonic lethality, demonstrating that complete absence of POLA1 function is incompatible with viability. Clinical and genomic characterization of a three-generation family with Xp22.11-p21.3 microdeletion encompassing POLA1; X-inactivation skewing analysis; reproductive outcome tracking across generations European journal of medical genetics Low 36182037

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1984 Method for determining whether a gene of Escherichia coli is essential: application to the polA gene. Journal of bacteriology 234 6233260
1975 Comparative analysis of deletion and base-change mutabilities of Escherichia coli B strains differing in DNA repair capacity (wild-type, uvrA-, polA-, recA-) by various mutagens. Mutation research 155 164624
1982 Nucleotide sequence of the Escherichia coli polA gene and primary structure of DNA polymerase I. The Journal of biological chemistry 154 6276402
2003 POLN, a nuclear PolA family DNA polymerase homologous to the DNA cross-link sensitivity protein Mus308. The Journal of biological chemistry 94 12794064
1999 Age-related macular degeneration and antioxidant status in the POLA study. POLA Study Group. Pathologies Oculaires Liées à l'Age. Archives of ophthalmology (Chicago, Ill. : 1960) 94 10532448
1989 Characterization of the polA gene of Streptococcus pneumoniae and comparison of the DNA polymerase I it encodes to homologous enzymes from Escherichia coli and phage T7. The Journal of biological chemistry 81 2537309
1973 Evidence for the control by exrA and polA genes of two branches of the uvr gene-dependent excision repair pathway in Escherichia coli K-12. Journal of bacteriology 69 4583206
1974 Separate branches of the uvr gene-dependent excision repair process in ultraviolet-irradiated Escherichia coli K-12 cells; their dependence upon growth medium and the polA, recA, recB, and exrA genes. Journal of bacteriology 68 4590484
1985 Genetic mapping and DNA sequence analysis of mutations in the polA gene of Escherichia coli. Journal of molecular biology 67 3910840
2000 A set of temperature sensitive-replication/-segregation and temperature resistant plasmid vectors with different copy numbers and in an isogenic background (chloramphenicol, kanamycin, lacZ, repA, par, polA). Gene 65 10607913
1975 Elevated mutability of polA derivatives of Escherichia coli B/r at sublethal doses of ultraviolet light: evidence for an inducible error-prone repair system ("SOS repair") and its anomalous expression in these strains. Genetics 56 1097302
2013 Retinal vascular caliber is associated with cardiovascular biomarkers of oxidative stress and inflammation: the POLA study. PloS one 51 23923054
1987 DNA sequence analysis of spontaneous mutation in a PolA1 strain of Escherichia coli indicates sequence-specific effects. Molecular & general genetics : MGG 45 3302596
1973 X-ray sensitivity and repair capacity of a polA1 exrA strain of Escherichia coli K-12. Journal of bacteriology 42 4572706
1995 The mechanism of recA polA lethality: suppression by RecA-independent recombination repair activated by the lexA(Def) mutation in Escherichia coli. Genetics 41 7789754
1979 Characterization of lambdapolA transducing phages; effective expression of the E. coli polA gene. Molecular & general genetics : MGG 41 159999
1982 Identification of two genes immediately downstream from the polA gene of Escherichia coli. Journal of bacteriology 40 6183253
1996 Construction by homologous recombination and phenotypic characterization of a DNA polymerase domain polA mutant of Mycobacterium smegmatis. Gene 37 8921903
1988 Induction of an abortive and futile DNA repair process in E. coli by the antitumor DNA bifunctional intercalator, ditercalinium: role in polA in death induction. Nucleic acids research 37 2830590
2003 Associations of cataract with antioxidant enzymes and other risk factors: the French Age-Related Eye Diseases (POLA) Prospective Study. Ophthalmology 35 14644713
1995 The Mycobacterium leprae genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel polA locus associated with genomic variability. Molecular microbiology 33 7476188
1982 A gene between polA and glnA retards growth of Escherichia coli when present in multiple copies: physiological effects of the gene for spot 42 RNA. Journal of bacteriology 32 6183252
1987 Role of DNA polymerase I in postreplication repair: a reexamination with Escherichia coli delta polA. Journal of bacteriology 31 3308845
2021 Immune Dysfunction in Mendelian Disorders of POLA1 Deficiency. Journal of clinical immunology 29 33392852
1982 Anaerobic incubation enhances the colony formation of a polA recB strain of Escherichia coli K-12. Journal of bacteriology 29 6288657
1979 Deletion mapping of the polA-metB region of the Escherichia coli chromosome. Journal of bacteriology 28 35528
2019 Symmetric activity of DNA polymerases at and recruitment of exonuclease ExoR and of PolA to the Bacillus subtilis replication forks. Nucleic acids research 25 31251806
1980 Mapping of the polA locus of Escherichia coli K12: genetic fine structure of the cistron. Genetics 25 7000617
2023 The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2. Oncogene 24 37391593
1995 Functional recA, lexA, umuD, umuC, polA, and polB genes are not required for the Escherichia coli UVM response. Journal of bacteriology 23 7592365
2005 Albumin and transthyretin as risk factors for cataract: the POLA study. Archives of ophthalmology (Chicago, Ill. : 1960) 22 15710820
2023 RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. Annals of hematology 21 37171597
1976 Spontaneous and induced mutability or frameshift strains of Salmonella typhimurium carrying uvrB and polA mutations. Mutation research 21 765803
2025 Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20 40991874
1983 Genetic characterization of early amber mutations in the Escherichia coli polA gene and purification of the amber peptides. Journal of molecular biology 20 6302278
1972 Replication of Phi-X174 DNA by Escherichia coli polA- in vitro (Phi-X174 DNA-DNA replication-E. coli polA-). Proceedings of the National Academy of Sciences of the United States of America 20 4550507
2021 Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. The oncologist 19 33524191
1974 Time scale for rejoining of bacteriophage lambda deoxyribonucleic acid molecules in superinfected pol+ and polA1 strains of Escherichia coli after exposure to 4 MeV electrons. Journal of bacteriology 18 4605387
1990 Mutations within the replicon of the IncN plasmid pCU1 that affect its Escherichia coli polA-independence but not its autonomous replication ability. Gene 17 2205534
1984 Frameshift mutagenesis by acridines in wild-type, uvrB and polA strains of Salmonella typhimurium with and without plasmid pKM101. Mutation research 17 6387482
2012 PolA1, a putative DNA polymerase I, is coexpressed with PerR and contributes to peroxide stress defenses of group A Streptococcus. Journal of bacteriology 16 23204468
2005 Escherichia coli mutator (Delta)polA is defective in base mismatch correction: the nature of in vivo DNA replication errors. Journal of molecular biology 16 16005896
1982 Powerful mutator activity of the polA1 mutation within the histidine region of Escherichia coli K-12. Journal of bacteriology 16 7037745
1993 A PCR method for the sequence analysis of the gyrA, polA and rnhA gene segments from mycobacteria. Gene 15 8294019
1993 YAC clone contigs surrounding the Zfx and Pola loci on the mouse X chromosome. Genomics 15 8406471
1990 DNA sequence analysis of spontaneous histidine mutations in a polA1 strain of Escherichia coli K12 suggests a specific role of the GTGG sequence. Molecular & general genetics : MGG 15 2270088
1987 Complementation of Bacillus subtilis polA mutants by DNA polymerase I from Streptococcus pneumoniae. Molecular & general genetics : MGG 15 3125407
1986 Repair of near-ultraviolet (365 nm)-induced strand breaks in Escherichia coli DNA. The role of the polA and recA gene products. Biophysical journal 15 3513859
1984 Escherichia coli DNA polymerase I. Construction of a polA plasmid for amplification and an improved purification scheme. The Journal of biological chemistry 14 6088498
1980 Construction and characterization of Escherichia coli polA-lacZ gene fusions. Journal of bacteriology 14 6445899
2025 Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis. Blood research 13 39907880
1999 DNA sequence analysis of spontaneous tonB deletion mutations in a polA1 strain of Escherichia coli K12. Biochemical and biophysical research communications 13 10441470
2020 Novel adamantyl retinoid-related molecules with POLA1 inhibitory activity. Bioorganic chemistry 12 32920362
2021 Antitumor activity of novel POLA1-HDAC11 dual inhibitors. European journal of medicinal chemistry 11 34772529
1993 Suppression of ColE1 high-copy-number mutants by mutations in the polA gene of Escherichia coli. Journal of bacteriology 11 8419292
1987 Streptococcus pneumoniae polA gene is expressed in Escherichia coli and can functionally substitute for the E. coli polA gene. Journal of bacteriology 11 2820948
1987 Frameshift mutagenesis by nitracrine analogues in wild-type, uvrB, polA and recA strains of Salmonella typhimurium, with and without plasmid pKM101. Mutation research 11 3037366
1976 Mapping of the polA locus of Escherichia coli K12: orientation in the amino- and carboxy-termini of the cistron. Molecular & general genetics : MGG 11 787765
2025 Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood advances 10 39908481
2017 Treponema pallidum ssp. pallidum identification by real-time PCR targetting the polA gene in paraffin-embedded samples positive by immunohistochemistry. International journal of STD & AIDS 10 28399709
1982 Plasmid R46-mediated protection against bleomycin is poLA+-dependent. Journal of general microbiology 9 6176674
2022 Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers 8 35205662
2013 Safeguarding Stem Cell-Based Regenerative Therapy against Iatrogenic Cancerogenesis: Transgenic Expression of DNASE1, DNASE1L3, DNASE2, DFFB Controlled By POLA1 Promoter in Proliferating and Directed Differentiation Resisting Human Autologous Pluripotent Induced Stem Cells Leads to their Death. Journal of stem cell research & therapy 8 25045589
1984 Biological effects of dyes on bacteria. VI. Mutation induction by acridine orange and methylene blue in the dark with special reference to Escherichia coli WP6 (polA1). Mutation research 8 6379434
1973 Comparison of the resA1 and polA1 mutations in isogenic strains of Escherichia coli K-12. Journal of bacteriology 8 4576410
2025 Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 7 40532125
2023 Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany. British journal of haematology 7 37188351
2019 YwqL (EndoV), ExoA and PolA act in a novel alternative excision pathway to repair deaminated DNA bases in Bacillus subtilis. PloS one 7 30726292
2024 Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL. Cancer treatment reviews 6 38310754
2022 Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study. Cancers 6 36428602
1994 Identification of YAC and cosmid clones encompassing the ZFX-POLA region using irradiation hybrid cell lines. Genomics 6 8020959
2025 Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL. Annals of hematology 5 40377673
2024 Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy. Neoplasia (New York, N.Y.) 5 39128273
1999 fcsA29 mutation is an allele of polA gene of Escherichia coli. Bioscience, biotechnology, and biochemistry 5 10192922
1994 Isolation of a DNA polymerase I (polA) mutant of Rhizobium leguminosarum that has significantly reduced levels of an IncQ-group plasmid. Molecular & general genetics : MGG 5 8190065
2022 Reactive oxygen species accumulation is synchronised with growth inhibition of temperature-sensitive recAts polA Escherichia coli. Archives of microbiology 4 35705748
2022 BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study. Journal of clinical medicine 4 35807041
2022 HslO ameliorates arrested ΔrecA polA cell growth and reduces DNA damage and oxidative stress responses. Scientific reports 4 36564489
2014 Malnutrition and retinal vascular caliber in the elderly: the POLA study. Investigative ophthalmology & visual science 4 24867580
1997 The RLEP-flanked polA gene from Mycobacterium leprae is not transcribed in Mycobacterium smegmatis. Gene 4 9073067
1981 The effects of mutations in the polA and recA genes on mutagenesis by nitrosoguanidine in Salmonella typhimurium. Mutation research 4 7035922
1980 [Relation between Escherichia coli K-12 viability and mutability and the balance between DNA and protein synthesis. III. Relation between disruptions in the balance between DNA and protein synthesis and mutagenesis and viability during thymidine deprivation of thy- cells defective with respect to recB and polA genes]. Genetika 4 6256261
1975 Excision of pyrimidine dimers in normal and T4-infected Escherichia coli: effect of polA and other mutations. Biochimica et biophysica acta 4 1091300
2025 Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model. BMJ open 3 39832983
2025 Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study. Annals of hematology 3 41068304
1997 Treatment with DNA-damaging agents increases expression of polA'-'lacZ gene fusions in Escherichia coli K-12. Molecular & general genetics : MGG 3 9108296
1984 Plasmid cloning and expression of the E. coli polA (+) gene in S. cerevisiae. Current genetics 3 24177812
1977 [Intergeneric conjugational crossing of Escherichia coli with Salmonella typhimurium. II. Transfer of a polA1 mutation from Escherichia coli to Salmonella typhimurium and its phenotypic expression in the salmonella genome]. Genetika 3 355054
2025 Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0-1 DLBCL patients : Article type: research. Annals of hematology 2 40728626
2023 [Autologous stem cell transplantation after pola-BR regimen as a salvage therapy in relapsed diffuse large B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology 2 37019676
2021 A patient with POLA1 splice variant expands the yet evolving phenotype of Van Esch O'Driscoll syndrome. European journal of medical genetics 2 34119699
1975 Dependence upon growth medium and the polA, polC, recA, recB, recC, and exrA genes of separate branches of the uvr Gene-dependent excision-repair process in Escherichia coli K12 cells. Basic life sciences 2 1103861
2025 Successful Treatment of Methotrexate-associated Lymphoproliferative Disorder with the Pola-R-CHP Regimen. Internal medicine (Tokyo, Japan) 1 39757000
2023 Pola-R-CHP for frontline therapy in DLBCL: Are we saving money by spending more? British journal of haematology 1 37313856
2022 A Xp22.11-p21.3 microdeletion in a three-generation family supports male lethality of POLA1 nullisomy resulting in reduced fertility of female carriers. European journal of medical genetics 1 36182037
1988 Sensitivity of polA mutants of Escherichia coli K-12 to ozone and radiations. Mutagenesis 1 3045488
1987 Isolation of Haemophilus influenzae genes that suppress Escherichia coli polA mutations. Journal of bacteriology 1 3294801
1986 Enhanced instability of IncFII basic replicon by the polA mutation. Biochemical and biophysical research communications 1 3021157
1985 Modification of survival after ultraviolet light exposure in a wild-type and a polA strain of Escherichia coli B/r by preirradiation treatment with chloramphenicol or rifampin. Mutation research 1 3903485
1981 [Repair and mutagenesis in Escherichia coli cells on induction in the DNA of monoadducts and cross-links by light-activated 8-methoxypsoralen. Dependence on the uvrA and polA genes]. Genetika 1 7033042

Missed literature

Know a paper Affinage missed for POLA1? Flag it for the maintainers and the community.

No submissions yet.